Jeffrey Crawford, MD

Professor of Medicine
George Barth Geller Professor
Member of the Duke Cancer Institute
Campus mail 443 Seeley G. Mudd Bldg, Durham, NC 27710
Phone (919) 681-9509
Email address crawf006@mc.duke.edu

1. Lung cancer/new treatment approaches.
2. Clinical trials of hematopoietic growth factors, biological agents and targeted drug development.
3. Cancer in the elderly and supportive care

Accomplishments

1. Lead Investigator of the U. S. multicenter, randomized trial of Filgrastim (G-CSF, Neupogen) to reduce the morbidity of chemotherapy-related neutropenia, leading to FDA approval 2/91.
2. Lead Investigator of the U. S. multicenter, randomized trial of Vinorelbine (Navelbine) in treatment of patients with advanced non small cell carcinoma of lung (NSCLC), leading to FDA approval 12/94.
3. Principal Investigator in initial phase I clinical trials of stem cell factor (SCF), megakaryocyte growth and development factor (MGDF), pegylated granulocyte-colony-stimulating factor and other novel hematopoietic growth factors.

In Their Words

Education and Training

  • M.D., Ohio State University, 1974

Publications

Crawford, Jeffrey, Neelima Denduluri, Debra Patt, Xiaolong Jiao, Phuong Khanh Morrow, Jacob Garcia, Richard Barron, and Gary H. Lyman. “Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer..” In Support Care Cancer, 2019. https://doi.org/10.1007/s00520-019-04875-1.

PMID
31172284
Full Text

Tan, Irena, Thomas E. Stinchcombe, Neal E. Ready, Jeffrey Crawford, Michael B. Datto, Rebecca J. Nagy, Richard B. Lanman, Lin Gu, and Jeffrey M. Clarke. “Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: a single institution, retrospective cohort study..” Transl Lung Cancer Res 8, no. 3 (June 2019): 258–67. https://doi.org/10.21037/tlcr.2019.04.03.

PMID
31367539
Full Text

Langer, Corey J., Mary W. Redman, James L. Wade, Charu Aggarwal, Jeffrey D. Bradley, Jeffrey Crawford, Philip J. Stella, et al. “SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)..” J Thorac Oncol, May 31, 2019. https://doi.org/10.1016/j.jtho.2019.05.029.

PMID
31158500
Full Text

Ramalingam, Sendhilnathan, Michaela A. Dinan, and Jeffrey Crawford. “Survival Comparison in Patients with Stage IV Lung Cancer in Academic versus Community Centers in the United States..” J Thorac Oncol 13, no. 12 (December 2018): 1842–50. https://doi.org/10.1016/j.jtho.2018.09.007.

PMID
30312680
Full Text

Denduluri, Neelima, Gary H. Lyman, Yunfei Wang, Phuong Khanh Morrow, Richard Barron, Debra Patt, Debajyoti Bhowmik, et al. “Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer..” Clin Breast Cancer 18, no. 5 (October 2018): 380–86. https://doi.org/10.1016/j.clbc.2018.02.003.

PMID
29622384
Full Text

Kinsey, Emily, Elizabeth Ajazi, Xiaofei Wang, Mary Ann Mayzie Johnston, and Jeffrey Crawford. “Predictors of Physical and Functional Loss in Advanced-Stage Lung Cancer Patients Receiving Platinum Chemotherapy..” J Thorac Oncol 13, no. 9 (September 2018): 1294–1301. https://doi.org/10.1016/j.jtho.2018.05.029.

PMID
29981438
Full Text

Arantes, Luiz H., Jeffrey Crawford, Pere Gascon, Mark Latymer, Vincent Launay-Vacher, Catherine Rolland, Florian Scotte, and Jay Wish. “A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia..” Crit Rev Oncol Hematol 129 (September 2018): 79–90. https://doi.org/10.1016/j.critrevonc.2018.06.010.

PMID
30097240
Full Text

Vlahovic, Gordana, Kellen L. Meadows, Ace J. Hatch, Jingquan Jia, Andrew B. Nixon, Hope E. Uronis, Michael A. Morse, et al. “A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer..” Oncologist 23, no. 7 (July 2018): 782–90. https://doi.org/10.1634/theoncologist.2016-0377.

PMID
29572245
Full Text

Pages